Evidence map›Paper›PMID 39696609›Full record

ArticleAddiction science & clinical practice2024

Centering autonomy and choice to support oral PrEP utilization among people who inject drugs: qualitative lessons from HPTN 094 INTEGRA.

Amaya Perez-Brumer, Rose Schmidt, Rebecca Kennedy, Jordan E Lake, Yolanda R Villarreal, Sydney Bornstein, Irene Kuo, Omar Nieto, Julie Franks, Cecile Denis and 4 more

Registry-linked trialAbstract read
In one paragraph

Article in Addiction science & clinical practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04804027, which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04804027 no registry record found
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Amaya Perez-BrumerDalla Lana School of Public Health, University of Toronto, Toronto, Canada. a.perezbrumer@utoronto.ca.ORCID 0000-0003-2441-4358
Rose SchmidtDalla Lana School of Public Health, University of Toronto, Toronto, Canada.
Rebecca KennedyDivision of Infectious Diseases and Global Public Health, University of California, San Diego, San Diego, CA, USA.
Jordan E LakeDepartment of Internal Medicine, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA.
Yolanda R VillarrealDepartment of Internal Medicine, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA.
Sydney BornsteinDepartment of Family and Community Medicine, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA.
Irene KuoDepartment of Family and Community Medicine, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA.
Omar NietoGeorge Washington University Milken School of Public Health, Washington, DC, USA.
Julie FranksDepartment of Family Medicine, University of California, Los Angeles, CA, United States of America.
Cecile DenisColumbia University, ICAP Mailman School of Public Health, New York, NY, USA.
Nabila El-BasselPerelman School of Medicine, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.
Steve ShoptawDepartment of Family Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Peter DavidsonDivision of Infectious Diseases and Global Public Health, University of California, San Diego, San Diego, CA, USA.
Laramie R SmithDivision of Infectious Diseases and Global Public Health, University of California, San Diego, San Diego, CA, USA.

Funding

LOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI Sinead Delany-Moretlwe, RAPHAEL J LANDOVITZ · 2011 to 2026
$779.5M
SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Sung-Jae Lee · 1997 to 2026
$53.5M
UCLA AIDS Prevention and Treatment Clinical Trials UnitUM1AI069424 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Judith S. Currier, RAPHAEL J LANDOVITZ · 2012 to 2026
$51.8M
ICAP Clinical Trials UnitUM1AI154468 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI WAFAA M. EL-SADR, JESSICA E. JUSTMAN · 2021 to 2026
$13.0M
The District of Columbia Clinical Trials Unit (DC CTU)UM1AI154466 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI Sarah Henn, Manya Magnus · 2021 to 2026
$12.5M
Reducing HIV-related Intersectional Stigma and Risk among People who Inject Drugs in a High Risk International SettingR34DA059327 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SMITH, LARAMIE RAE · 2023 to 2025
$710k
CIHR CRC-2021-00132Foundation for the National Institutes of Health UM1AI068617-15NIAID NIH HHS UM1 AI068613NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI068619NIAID NIH HHS UM1 AI069424NIAID NIH HHS UM1 AI154466NIAID NIH HHS UM1 AI154468NIDA NIH HHS R34 DA059327NIMH NIH HHS P30 MH058107
6 · The paper itself

Abstract

backgroundOral Pre-exposure prophylaxis (PrEP) is effective in preventing HIV transmission. However, despite high rates of HIV risk behaviors among people who inject drugs (PWID), this population remains underserved by current HIV prevention efforts in the United States. To address this challenge, we conducted an in-depth exploration of perspectives on using oral PrEP among PWID engaged in the HIV Prevention Trials Network (HPTN) 094 INTEGRA Study.

methodsGuided by the Practical, Robust, Implementation, and Sustainability Model (PRISM), our qualitative study drew on semi-structured interviews conducted as part of the embedded implementation science evaluation of HPTN 094 INTEGRA. Seventy-seven PWID participants from five sites across New York City, Houston, Los Angeles, Philadelphia, and Washington DC were interviewed to assess intervention delivery, care access, and engagement sustainability. Audio files were transcribed verbatim and analyzed via an inductive and deductive thematic approach.

resultsMost participants (n = 46, 59.7%) discussed oral PrEP during their interview, though not directly prompted. Participants discussing PrEP had a mean age of 41.6 years and were predominantly white (54.3%) and cisgender men (60.9%). Among these, 15 participants described using PrEP. All participants had facilitated access to oral PrEP. Yet, the choice to use PrEP was influenced by personal risk perceptions, (mis)information about PrEP, and external factors (i.e. housing, financial security), which, for some, limited the autonomy to use PrEP. Two key themes emerged among participants using PrEP: ease of access and perceptions of high HIV risk. Those not using PrEP described two themes: low risk perception and prioritizing more urgent needs. Among participants not using PrEP a subgroup commonly described ambivalent interest, PrEP knowledge gaps, and PrEP readiness (i.e., contemplation).

conclusionsQualitative findings highlight that facilitated PrEP access was insufficient to motivate use for many participants. Rather, PrEP decision-making process (i.e., choice) was linked to risk perception and individuals' capability to leverage PrEP as a resource based on their circumstances (i.e., autonomy). Participants' descriptions of the centrality of choice and autonomy for PrEP use underscore that ease of access is a necessary pre-condition, but person-centered interventions should also address housing, financial stability, and urgent medical conditions to promote PrEP utilization among PWID. CLINICAL

trial registrationNCT04804027.

Indexed as

HIV InfectionsPre-Exposure ProphylaxisQualitative ResearchSubstance Abuse, IntravenousAdministration, OralAdultAnti-HIV AgentsChoice BehaviorFemaleHumansInterviews as TopicMaleMiddle AgedPersonal AutonomyRandomized Controlled Trials as TopicUnited StatesAnti-HIV AgentsHIV prevention trials networkIntegrated carePeople who inject drugsPre-exposure prophylaxisPrEPQualitative research

Identifiers

PMID39696609
PMCPMC11653907

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.